NextCure(NXTC) - 2024 Q1 - Quarterly Results

Exhibit 99.1 NextCure Provides Business Update and Reports First Quarter 2024 Financial Results BELTSVILLE, Md. – May 2, 2024 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first- in-class, and best-in-class therapies to treat cancer, today provided a business update and reported its first-quarter 2024 financial results. "We look forward to providing an update on the NC410 combo trial at the ASCO Annual Meeting, which will include d ...